Chronic Kidney Disease–Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027

Chronic Kidney Disease–Mineral Bone Disorders (CKD-MBD) is one of the many complications associated with overall CKD. The systemic disorder is identified from high parathyroid hormone and disrupted K+/Ca2+ levels caused by a decreasing glomerular filtration rate (GFR) due to renal impairment.

This report provides an assessment of the pipeline, clinical, and commercial landscape of CKD-MBD. Overall, GlobalData expects minimal changes to overall disease treatment, with exceptions being the launch of the novel NHE3 and novel CASR in the US and Japan markets respectively.

Scope

GlobalData’s CKD-MBD: Competitive Landscape to 2027 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

  • Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment—leading marketed products, current and future players
  • Competitive Landscape Analysis—key market events (2017–2027)

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global CKD-MBD market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CKD-MBD market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

Akebia

Astellas

Shire

Vifor

Abbvie

Fresenius

Abbott

Novadiol

Japan Tobacco Company

Daiichi-Sankyo

Shield

Spectrum

OPKO

Ardelyx

Sanofi Genzyme

Amgen

Akebia

Astellas

Shire

Vifor

Abbvie

Fresenius

Abbott

Novadiol

Japan Tobacco Company

Daiichi-Sankyo

Shield

Spectrum

OPKO

Ardelyx

Sanofi Genzyme

Amgen

Table of Contents

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 ...

Table of Contents (PowerPoint Deck)

1 Preface

1.1 Table of Contents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 Key Events

3 Introduction

3.1 Report Scope

3.2 Disease Overview & Epidemiology

4 Pipeline Assessment

4.1 Pipeline Overview

4.2 Pipeline Breakdown by Region/Country

4.3 Pipeline Breakdown by Molecule Type and Target

4.4 Drug Review Designations

4.5 Products in Clinical Development

5 Clinical Trial Assessment

5.1 Clinical Trials Overview

5.2 Top Sponors of Clinical Trials in CKD-MBD

5.3 Trial Breakdown by Region

5.4 Therapy Area Perspective

5.5 Enrollment Analytics

6 Commercial Assessment

6.1 Leading Marketed Products

6.2 Current & Future Players

7 Competitive Landscape Analysis (2017–2027)

7.1 Events and Segmentation Overview

7.2 US

7.3 5EU

7.4 Japan and China

8 Appendix

8.1 Sources

8.2 Methodology

8.3 Key Events Included in the Analysis

8.4 About the Authors

8.5 About GlobalData

8.6 Disclaimer

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports